The alpha7 nicotinic acetylcholine receptor as a pharmacological target for inflammation

British Journal of Pharmacology

Volumn 151, Issue 7, 2007, Pages 915-929

  De Jonge, W J ^a,b   Ulloa, L ^c,d  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^d UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

Author keywords

Acetylcholine; Cholinergic; Macrophage; NF B; Nicotine; Nicotinic agonist; Sepsis; STAT

Indexed keywords

3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; 3 (4 HYDROXY 2 METHOXYBENZYLIDINE); ACETYLCHOLINE; ARR 17779; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUNGAROTOXIN RECEPTOR; CAP 55; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; COTININE; CYTOKINE; EXO 2 (2 PYRIDYL) 7 AZABICYCLO[2.2.1]HEPTANE; GALANTAMINE; MESALAZINE; METRONIDAZOLE; N (1 AZABICYCLO[2.2.2]OCT 3 YL) 4 CHLOROBENZAMIDE; NEUROTRANSMITTER; NICOTINE; NICOTINIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PHYSOSTIGMINE; PLACEBO; PNU 282987; SEMAPIMOD; SPIRO(1 AZABICYCLO[2.2.2]OCTANE 3,5 OXAZOLIDIN 2 ONE); TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; B LYMPHOCYTE; BONE MARROW CELL; CELL FUNCTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CROHN DISEASE; CYTOKINE PRODUCTION; DENDRITIC CELL; DIZZINESS; DRUG DESIGN; DRUG DOSE INCREASE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG TARGETING; DRUG WITHDRAWAL; ENZYME ACTIVATION; GASTROINTESTINAL MOTILITY; HEART RATE; HORMONE RELEASE; HUMAN; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; INFECTION; INFLAMMATION; MACROPHAGE; MICROGLIA; MONOCYTE; NAUSEA; NERVE STIMULATION; NEUROTOXICITY; NEUTROPHIL; NONHUMAN; PANCREATITIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SLEEP DISORDER; T LYMPHOCYTE; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; VAGUS NERVE;

ANIMALS; DRUG DESIGN; HUMANS; INFLAMMATION; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE; NICOTINIC AGONISTS; RECEPTORS, NICOTINIC; SIGNAL TRANSDUCTION;

EID: 34547558959     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707264     Document Type: Review

References (119)

1. Abraham E, Anzueto A, Gutierrez G, Tessler S, San PG, Wunderink R et al. (1998). Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. vNORASEPT II Study Group. Lancet 351: 929-933.
2. Aicher A, Heeschen C, Mohaupt M, Cooke JP, Zeiher AM, Dimmeler S (2003). Nicotine strongly activates dendritic cell-mediated adaptive immunity: potential role for progression of atherosclerotic lesions. Circulation 107: 604-611.
3. Akk G, Steinbach JH (2005). Galantamine activates muscle-type nicotinic acetylcholine receptors without binding to the acetylcholine-binding site. J Neurosci 25: 1992-2001.
4. Aoshiba K, Nagai A, Yasui S, Konno K (1996). Nicotine prolongs neutrophil survival by suppressing apoptosis. J Lab Clin Med 127: 186-194.
5. Arredondo J, Chernyavsky AI, Jolkovsky DL, Pinkerton KE, Grando SA (2006). Receptor-mediated tobacco toxicity: cooperation of the Ras/Raf-1/MEK1/ERK and JAK-2/STAT-3 pathways downstream of alpha7 nicotinic receptor in oral keratinocytes. FASEB J 20: 2093-2101.
6. Backhed F, Ley RE, Sonnenburg JL, Peterson DA, Gordon JI (2005). Host-bacterial mutualism in the human intestine. Science 307: 1915-1920.
7. Barnes PJ (2003). New concepts in chronic obstructive pulmonary disease. Annu Rev Med 54: 113-129.
8. Berg DK, Conroy WG (2002). Nicotinic alpha 7 receptors: synaptic options and downstream signaling in neurons. J Neurobiol 53: 512-523.
9. Bernik TR, Friedman SG, Ochani M, DiRaimo R, Ulloa L, Yang H et al. (2002). Pharmacological stimulation of the cholinergic antiinflammatory pathway. J Exp Med 195: 781-788.
10. Bertrand D, Galzi JL, Villers-Thiery A, Bertrand S, Changeux JP (1993). Mutations at two distinct sites within the channel domain M2 alter calcium permeability of neuronal alpha 7 nicotinic receptor. Proc Natl Acad Sci USA 90: 6971-6975.
11. Blanchet MR, Israel-Assayag E, Daleau P, Beaulieu MJ, Cormier Y (2006). Dimethyphenylpiperazinium, a nicotinic receptor agonist, downregulates inflammation in monocytes/macrophages through PI3 K and PLC chronic activation. Am J Physiol Lung Cell Mol Physiol 291: L757-L763.
12. Borovikova LV, Ivanova S, Zhang M, Yang H, Botchkina GI, Watkins LR et al. (2000). Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 405: 458-462.
13. Bouzat C, Gumilar F, Spitzmaul G, Wang HL, Rayes D, Hansen SB et al. (2004). Coupling of agonist binding to channel gating in an ACh-binding protein linked to an ion channel. Nature 430: 896-900.
14. Boyd RT (1997). The molecular biology of neuronal nicotinic acetylcholine receptors. Crit Rev Toxicol 27: 299-318.
15. Charpantier E, Wiesner A, Huh KH, Ogier R, Hoda JC, Allaman G et al. (2005). Alpha7 neuronal nicotinic acetylcholine receptors are negatively regulated by tyrosine phosphorylation and Src-family kinases. J Neurosci 25: 9836-9849.
16. Colquhoun LM, Patrick JW (1997). Pharmacology of neuronal nicotinic acetylcholine receptor subtypes. Adv Pharmacol 39: 191-220.
17. Davies BD, Hoss W, Lin JP, Lionetti F (1982). Evidence for a noncholinergic nicotine receptor on human phagocytic leukocytes. Mol Cell Biochem 44: 23-31.
18. De Jonge WJ, van der Zanden EP, The FO, Bijlsma MF, van Westerloo DJ, Bennink RJ et al. (2005). Stimulation of the vagus nerve attenuates macrophage activation by activating the Jak2-STAT3 signaling pathway. Nat Immunol 6: 844-851.
19. De SR, Jmone-Cat MA, Carnevale D, Minghetti L (2005). Activation of alpha7 nicotinic acetylcholine receptor by nicotine selectively up-regulates cyclooxygenase-2 and prostaglandin E2 in rat microglial cultures. J Neuroinflammation 2: 4.
20. DeRosa MJ, Esandi MC, Garelli A, Rayes D, Bouzat C (2005). Relationship between alpha 7nAChR and apoptosis in human lymphocytes. J Neuroimmunol 160: 154-161.
21. Downing JE, Miyan JA (2000). Neural immunoregulation: emerging roles for nerves in immune homeostasis and disease. Immunol Today 21: 281-289.
22. Driessler F, Venstrom K, Sabat R, Asadullah K, Schottelius AJ (2004). Molecular mechanisms of interleukin-10-mediated inhibition of NF-kappaB activity: a role for p50. Clin Exp Immunol 135: 64-73.
23. Drisdel RC, Green WN (2000). Neuronal alpha-bungarotoxin receptors are alpha7 subunit homomers. J Neurosci 20: 133-139.
24. Feldmann M (2002). Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol 2: 364-371.
25. Fujii T, Tajima S, Yamada S, Watanabe Y, Sato KZ, Matsui M et al. (1999). Constitutive expression of mRNA for the same choline acetyltransferase as that in the nervous system, an acetylcholine-synthesizing enzyme, in human leukemic T-cell lines. Neurosci Lett 259: 71-74.
26. Gahring LC, Rogers SW (2005). Neuronal nicotinic acetylcholine receptor expression and function on nonneuronal cells. AAPS J 7: E885-E894.
27. Galzi JL, Bertrand D, Villers-Thiery A, Revah F, Bertrand S, Changeux JP (1991). Functional significance of aromatic amino acids from three peptide loops of the alpha 7 neuronal nicotinic receptor site investigated by site-directed mutagenesis. FEBS Lett 294: 198-202.
28. Gault J, Hopkins J, Berger R, Drebing C, Logel J, Walton C et al. (2003). Comparison of polymorphisms in the alpha7 nicotinic receptor gene and its partial duplication in schizophrenic and control subjects. Am J Med Genet B Neuropsychiatr Genet 123: 39-49.
29. Gault J, Robinson M, Berger R, Drebing C, Logel J, Hopkins J et al. (1998). Genomic organization and partial duplication of the human alpha7 neuronal nicotinic acetylcholine receptor gene (CHRNA7). Genomics 52: 173-185.
30. Ghia JE, Blennerhassett P, Kumar-Ondiveeran H, Verdu EF, Collins SM (2006). The vagus nerve: a tonic inhibitory influence associated with inflammatory bowel disease in a murine model. Gastroenterology 131: 1122-1130.
31. Green GM, Carolin D (1967). The depressant effect of cigarette smoke on the in vitro antibacterial activity of alveolar macrophages. N Engl J Med 276: 421-427.
32. Guinet E, Yoshida K, Nouri-Shirazi M (2004). Nicotinic environment affects the differentiation and functional maturation of monocytes derived dendritic cells (DCs). Immunol Lett 95: 45-55.
33. Hamano R, Takahashi HK, Iwagaki H, Yoshino T, Nishibori M, Tanaka N (2006). Stimulation of alpha7 nicotinic acetylcholine receptor inhibits CD14 and the toll-like receptor 4 expression in human monocytes. Shock 26: 358-364.
34. Heeschen C, Jang JJ, Weis M, Pathak A, Kaji S, Hu RS et al. (2001). Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis. Nat Med 7: 833-839.
35. Hellstrom-Lindahl E (2000). Modulation of beta-amyloid precursor protein processing and tau phosphorylation by acetylcholine receptors. Eur J Pharmacol 393: 255-263.
36. Hellstrom-Lindahl E, Mousavi M, Ravid R, Nordberg A (2004). Reduced levels of Abeta 40 and Abeta 42 in brains of smoking controls and Alzheimer's patients. Neurobiol Dis 15: 351-360.
37. Hoentjen F, Sartor RB, Ozaki M, Jobin C (2005). STAT3 regulates NF-kappaB recruitment to the IL-12p40 promoter in dendritic cells. Blood 105: 689-696.
38. Hotchkiss RS, Karl IE (2003). The pathophysiology and treatment of sepsis. N Engl J Med 348: 138-150.
39. Huston JM, Ochani M, Rosas-Ballina M, Liao H, Ochani K, Pavlov VA et al. (2006). Splenectomy inactivates the cholinergic antiinflammatory pathway during lethal endotoxemia and polymicrobial sepsis. J Exp Med 203: 1623-1628.
40. Iho S, Tanaka Y, Takauji R, Kobayashi C, Muramatsu I, Iwasaki H et al. (2003). Nicotine induces human neutrophils to produce IL-8 through the generation of peroxynitrite and subsequent activation of NF-kappaB. J Leukoc Biol 74: 942-951.
41. Ingram JR, Thomas GA, Rhodes J, Green JT, Hawkes ND, Swift JL et al. (2005). A randomized trial of nicotine enemas for active ulcerative colitis. Clin Gastroenterol Hepatol 3: 1107-1114.
42. Jenkins BJ, Grail D, Nheu T, Najdovska M, Wang B, Waring P et al. (2005). Hyperactivation of Stat3 in gp130 mutant mice promotes gastric hyperproliferation and desensitizes TGF-beta signaling. Nat Med 11: 845-852.
43. Kawashima K, Fujii T (2003). The lymphocytic cholinergic system and its contribution to the regulation of immune activity. Life Sci 74: 675-696.
44. Kawashima K, Fujii T (2004). Expression of non-neuronal acetylcholine in lymphocytes and its contribution to the regulation of immune function. Front Biosci 9: 2063-2085.
45. Khiroug SS, Harkness PC, Lamb PW, Sudweeks SN, Khiroug L, Millar NS et al. (2002). Rat nicotinic ACh receptor alpha7 and beta2 subunits co-assemble to form functional heteromeric nicotinic receptor channels. J Physiol 540: 425-434.
46. Kitagawa H, Takenouchi T, Azuma R, Wesnes KA, Kramer WG, Clody DE et al. (2003). Safety, pharmacokinetics, and effects on cognitive function of multiple doses of GTS-21 in healthy, male volunteers. Neuropsychopharmacology 28: 542-551.
47. Levy DE, Lee CK (2002). What does Stat3 do? J Clin Invest 109: 1143-1148.
48. Lloyd GK, Williams M (2000). Neuronal nicotinic acetylcholine receptors as novel drug targets. J Pharmacol Exp Ther 292: 461-467.
49. Lukas RJ, Changeux JP, Le Novere N, Albuquerque EX, Balfour DJ, Berg DK et al. (1999). International Union of Pharmacology. XX. Current status of the nomenclature for nicotinic acetylcholine receptors and their subunits. Pharmacol Rev 51: 397-401.
50. Luyer MD, Greve JW, Hadfoune M, Jacobs JA, Dejong CH, Buurman WA (2005). Nutritional stimulation of cholecystokinin receptors inhibits inflammation via the vagus nerve. J Exp Med 202: 1023-1029.
51. Mandavilli A (2004). Nicotine fix. Nat Med 10: 660-661.
52. Marrero MB, Papke RL, Bhatti BS, Shaw S, Bencherif M (2004). The neuroprotective effect of 2-(3-pyridyl)-1-azabicyclo[3.2.2]nonane (TC-1698), a novel alpha7 ligand, is prevented through angiotensin II activation of a tyrosine phosphatase. J Pharmacol Exp Ther 309: 16-27.
53. Martin GS, Mannino DM, Eaton S, Moss M (2003). The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348: 1546-1554.
54. Martin LF, Kem WR, Freedman R (2004). Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia. Psychopharmacology (Berl) 174: 54-64.
55. Matsunaga K, Klein TW, Friedman H, Yamamoto Y (2001). Involvement of nicotinic acetylcholine receptors in suppression of antimicrobial activity and cytokine responses of alveolar macrophages to Legionella pneumophila infection by nicotine. J Immunol 167: 6518-6524.
56. Meyer EM, Kuryatov A, Gerzanich V, Lindstrom J, Papke RL (1998). Analysis of 3-(4-hydroxy, 2-Methoxybenzylidene)anabaseine selectivity and activity at human and rat alpha-7 nicotinic receptors. J Pharmacol Exp Ther 287: 918-925.
57. Miyazawa A, Fujiyoshi Y, Unwin N (2003). Structure and gating mechanism of the acetylcholine receptor pore. Nature 423: 949-955.
58. Murray PJ (2005). The primary mechanism of the IL-10-regulated antiinflammatory response is to selectively inhibit transcription. Proc Natl Acad Sci USA 102: 8686-8691.
59. Nizri E, Hamra-Amitay Y, Sicsic C, Lavon I, Brenner T (2006). Antiinflammatory properties of cholinergic up-regulation: a new role for acetylcholinesterase inhibitors. Neuropharmacology 50: 540-547.
60. Nouri-Shirazi M, Guinet E (2003). Evidence for the immunosuppressive role of nicotine on human dendritic cell functions. Immunology 109: 365-373.
61. Nuorti JP, Butler JC, Farley MM, Harrison LH, McGeer A, Kolczak MS et al. (2000). Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team. N Engl J Med 342: 681-689.
62. Olincy A, Harris JG, Johnson LL, Pender V, Kongs S, Allensworth D et al. (2006). Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry 63: 630-638.
63. Ortega E, Barriga C, Rodriguez AB (1994). Decline in the phagocytic function of alveolar macrophages from mice exposed to cigarette smoke. Comp Immunol Microbiol Infect Dis 17: 77-84.
64. Papadopoulos NG, Alamanos Y, Voulgari PV, Epagelis EK, Tsifetaki N, Drosos AA (2005). Does cigarette smoking influence disease expression, activity and severity in early rheumatoid arthritis patients? Clin Exp Rheumatol 23: 861-866.
65. Pullan RD, Rhodes J, Ganesh S, Mani V, Morris JS, Williams GT et al. (1994). Transdermal nicotine for active ulcerative colitis. N Engl J Med 330: 811-815.
66. Rakhilin S, Drisdel RC, Sagher D, McGehee DS, Vallejo Y, Green WN (1999). alpha-bungarotoxin receptors contain alpha7 subunits in two different disulfide-bonded conformations. J Cell Biol 146: 203-218.
67. Rangwala F, Drisdel RC, Rakhilin S, Ko E, Atluri P, Harkins AB et al. (1997). Neuronal alpha-bungarotoxin receptors differ structurally from other nicotinic acetylcholine receptors. J Neurosci 17: 8201-8212.
68. Rice TW, Bernard GR (2005). Therapeutic intervention and targets for sepsis. Annu Rev Med 56: 225-248.
69. Rinner I, Kawashima K, Schauenstein K (1998). Rat lymphocytes produce and secrete acetylcholine in dependence of differentiation and activation. J Neuroimmunol 81: 31-37.
70. Rioux N, Castonguay A (2000). The induction of cyclooxygenase-1 by a tobacco carcinogen in U937 human macrophages is correlated to the activation of NF-kappaB. Carcinogenesis 21: 1745-1751.
71. Rubin DT, Hanauer SB (2000). Smoking and inflammatory bowel disease. Eur J Gastroenterol Hepatol 12: 855-862.
72. Rutgeerts P, Van AG, Vermeire S (2006). Review article: infliximab therapy for inflammatory bowel disease - seven years on. Aliment Pharmacol Ther 23: 451-463.
73. Saeed RW, Varma S, Peng-Nemeroff T, Sherry B, Balakhaneh D, Huston J et al. (2005). Cholinergic stimulation blocks endothelial cell activation and leukocyte recruitment during inflammation. J Exp Med 201: 1113-1123.
74. Sansonetti PJ (2006). The innate signaling of dangers and the dangers of innate signaling. Nat Immunol 7: 1237-1242.
75. Sato KZ, Fujii T, Watanabe Y, Yamada S, Ando T, Kazuko F et al. (1999). Diversity of mRNA expression for muscarinic acetylcholine receptor subtypes and neuronal nicotinic acetylcholine receptor subunits in human mononuclear leukocytes and leukemic cell lines. Neurosci Lett 266: 17-20.
76. Schottelius AJ, Mayo MW, Sartor RB, Baldwin Jr AS (1999). Interleukin-10 signaling blocks inhibitor of kappaB kinase activity and nuclear factor kappaB DNA binding. J Biol Chem 274: 31868-31874.
77. Schwartz SL (1976). Interaction of nicotine and other amines with the endocytic and exocytic functions of macrophages. Fed Proc 35: 85-88.
78. Schwartz SL, Evans DE, Lundin JE, Bond JC (1972). Inhibition of pinocytosis by nicotine. J Pharmacol Exp Ther 183: 370-377.
79. Severance EG, Zhang H, Cruz Y, Pakhlevaniants S, Hadley SH, Amin J et al. (2004). The alpha7 nicotinic acetylcholine receptor subunit exists in two isoforms that contribute to functional ligand-gated ion channels. Mol Pharmacol 66: 420-429.
80. Shaw S, Bencherif M, Marrero MB (2002). Janus kinase 2, an early target of alpha 7 nicotinic acetylcholine receptor-mediated neuroprotection against Abeta-(1-42) amyloid. J Biol Chem 277: 44920-44924.
81. Shaw S, Bencherif M, Marrero MB (2003). Angiotensin II blocks nicotine-mediated neuroprotection against beta-amyloid (1-42) via activation of the tyrosine phosphatase SHP-1. J Neurosci 23: 11224-11228.
82. Shytle RD, Mori T, Townsend K, Vendrame M, Sun N, Zeng J et al. (2004). Cholinergic modulation of microglial activation by alpha 7 nicotinic receptors. J Neurochem 89: 337-343.
83. Skok M, Grailhe R, Agenes F, Changeux JP (2006). The role of nicotinic acetylcholine receptors in lymphocyte development. J Neuroimmunol 171: 86-98.
84. Skok M, Grailhe R, Changeux JP (2005). Nicotinic receptors regulate B lymphocyte activation and immune response. Eur J Pharmacol 517: 246-251.
85. Sopori M (2002). Effects of cigarette smoke on the immune system. Nat Rev Immunol 2: 372-377.
86. Sopori ML, Kozak W, Savage SM, Geng Y, Soszynski D, Kluger MJ et al. (1998). Effect of nicotine on the immune system: possible regulation of immune responses by central and peripheral mechanisms. Psychoneuroendocrinology 23: 189-204.
87. Sorensen LT, Nielsen HB, Kharazmi A, Gottrup F (2004). Effect of smoking and abstention on oxidative burst and reactivity of neutrophils and monocytes. Surgery 136: 1047-1053.
88. Speer P, Zhang Y, Gu Y, Lucas MJ, Wang Y (2002). Effects of nicotine on intercellular adhesion molecule expression in endothelial cells and integrin expression in neutrophils in vitro. Am J Obstet Gynecol 186: 551-556.
89. Stead RH, Colley EC, Wang B, Partosoedarso E, Lin J, Stanisz A et al. (2006). Vagal influences over mast cells. Auton Neurosci 125: 53-61.
90. Streit WJ (2002). Microglia as neuroprotective, immunocompetent cells of the CNS. Glia 40: 133-139.
91. Sugano N, Shimada K, Ito K, Murai S (1998). Nicotine inhibits the production of inflammatory mediators in U937 cells through modulation of nuclear factor-kappaB activation. Biochem Biophys Res Commun 252: 25-28.
92. Suzuki T, Hide I, Matsubara A, Hama C, Harada K, Miyano K et al. (2006). Microglial alpha7 nicotinic acetylcholine receptors drive a phospholipase C/IP3 pathway and modulate the cell activation toward a neuroprotective role. J Neurosci Res 83: 1461-1470.
93. Takahashi HK, Iwagaki H, Hamano R, Yoshino T, Tanaka N, Nishibori M (2006). alpha7 Nicotinic Acetylcholine Receptor Stimulation Inhibits Lipopolysaccharide-Induced Interleukin-18 and -12 Production in Monocytes. J Pharmacol Sci 102: 143-146.
94. Takeda K, Clausen BE, Kaisho T, Tsujimura T, Terada N, Forster I et al. (1999). Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 10: 39-49.
95. Theodorou V, Fioramonti J, Bueno L (1996). Integrative neuroimmunology of the digestive tract. Vet Res 27: 427-442.
96. Thomas GA, Rhodes J, Ingram JR (2005). Mechanisms of disease: nicotine-a review of its actions in the context of gastrointestinal disease. Nat Clin Pract Gastroenterol Hepatol 2: 536-544.
97. Thyberg J, Hedin U, Stenseth K, Nilsson J (1983). Effects of nicotine on the fine structure of cultivated mouse peritoneal macrophages. Acta Pathol Microbiol Immunol Scand [A] 91: 23-30.
98. Totti III N, McCusker KT, Campbell EJ, Griffin GL, Senior RM (1984). Nicotine is chemotactic for neutrophils and enhances neutrophil responsiveness to chemotactic peptides. Science 223: 169-171.
99. Tracey KJ (2002). The inflammatory reflex. Nature 420: 853-859.
100. Ulloa L (2005). The vagus nerve and the nicotinic anti-inflammatory pathway. Nat Rev Drug Discov 4: 673-684.
101. Ulloa L, Doody J, Massague J (1999). Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway. Nature 397: 710-713.
102. Ulloa L, Messmer D (2006). High-mobility group box 1 (HMGB1) protein: friend and foe. Cytokine Growth Factor Rev 17: 189-201.
103. Ulloa L, Tracey KJ (2005). The 'cytokine profile': a code for sepsis. Trends Mol Med 11: 56-63.
104. Van Assche G, Vermeire S, Rutgeerts P (2005). Medical treatment of inflammatory bowel diseases. Curr Opin Gastroenterol 21: 443-447.
105. van der Poll T, Lowry SF (1995). Tumor necrosis factor in sepsis: mediator of multiple organ failure or essential part of host defense? Shock 3: 1-12.
106. van Westerloo DJ, Giebelen IA, Florquin S, Bruno MJ, Larosa GJ, Ulloa L et al. (2006). The vagus nerve and nicotinic receptors modulate experimental pancreatitis severity in mice. Gastroenterology 130: 1822-1830.
107. Villiger Y, Szanto I, Jaconi S, Blanchet C, Buisson B, Krause KH et al. (2002). Expression of an alpha7 duplicate nicotinic acetylcholine receptor-related protein in human leukocytes. J Neuroimmunol 126: 86-98.
108. Wang H, Liao H, Ochani M, Justiniani M, Lin X, Yang L et al. (2004). Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat Med 10: 1216-1221.
109. Wang H, Yu M, Ochani M, Amella CA, Tanovic M, Susarla S et al. (2003). Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 421: 384-388.
110. Wang HY, Lee DH, D'Andrea MR, Peterson PA, Shank RP, Reitz AB (2000a). beta-Amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology. J Biol Chem 275: 5626-5632.
111. Wang HY, Lee DH, Davis CB, Shank RP (2000b). Amyloid peptide Abeta(1-42) binds selectively and with picomolar affinity to alpha7 nicotinic acetylcholine receptors. J Neurochem 75: 1155-1161.
112. Wang P, Wu P, Siegel MI, Egan RW, Billah MM (1995). Interleukin (IL)-10 inhibits nuclear factor kappa B (NF kappa B) activation in human monocytes. IL-10 and IL-4 suppress cytokine synthesis by different mechanisms. J Biol Chem 270: 9558-9563.
113. Williams LM, Ricchetti G, Sarma U, Smallie T, Foxwell BM (2004). Interleukin-10 suppression of myeloid cell activation - a continuing puzzle. Immunology 113: 281-292.
114. Williams ME, Burton B, Urrutia A, Shcherbatko A, Chavez-Noriega LE, Cohen CJ et al. (2005). Ric-3 promotes functional expression of the nicotinic acetylcholine receptor alpha7 subunit in mammalian cells. J Biol Chem 280: 1257-1263.
115. Yoshida Y, Kumar A, Koyama Y, Peng H, Arman A, Boch JA et al. (2004). Interleukin 1 activates STAT3/nuclear factor-kappaB cross-talk via a unique T. J Biol Chem 279: 1768-1776.
116. Yu Z, Kone BC (2004). The STAT3 DNA-binding domain mediates interaction with NF-kappaB p65 and iuducible nitric oxide synthase transrepression in mesangial cells. J Am Soc Nephrol 15: 585-591.
117. Yu Z, Zhang W, Kone BC (2002). Signal transducers and activators of transcription 3 (STAT3) inhibits transcription of the inducible nitric oxide synthase gene by interacting with nuclear factor kappaB. Biochem J 367: 97-105.
118. Zhang J, Rivest S (2001). Anti-inflammatory effects of prostaglandin E2 in the central nervous system in response to brain injury and circulating lipopolysaccharide. J Neurochem 76: 855-864.
119. Zijlstra FJ, Srivastava ED, Rhodes M, van Dijk AP, Fogg F, Samson HJ et al. (1994). Effect of nicotine on rectal mucus and mucosal eicosanoids. Gut 35: 247-251.